Saturday, August 09, 2025 1:34:46 PM
I'm just sitting here thinking through the Friday halt, and thought I'd share my thoughts.
Why would a CEO initiate a halt on Friday, with a goal date the next day? We can assume he received a decision from FDA. If that's the case, why the halt? Many believe it is because he didn't want news to leak out. This doesn't add up, because this is a small group of people, and not a huge corporation, with hundreds of executives to be concerned with about spilling the beans. In fact, it is likely that he himself, was the only one privy to the information. It's possible this was done to avoid perception of insider trading, but as stated earlier, the insider class is small.
If the news was bad, (delay or denial) why halt the stock? He could have allowed the stock to trade out, and released the news after the market close, which he didn't. On the other hand, if the news is good, what better way to send a message or flare to the market and investors to stay tuned. In other words, why halt the stock, drawing attention to it, and then release disappointing news? That would make no sense.
Some might argue the CEO can't initiate a halt like that, but on the TSX he can, and the OTC has to follow suit. The authorities and exchange wouldn't be privy to a news event, and they don't halt automatically because of an upcoming goal date.
In the past CRL's and delays didn't cause a halt. In my opinion, they have their approval, and the CEO is taking his time writing and preparing his PR, and how and where it will be released.
I don't usually like to post information, that might cause someone to buy and lose money. However, this is safe situation, because we will all find out together.
Hey, it's only my thoughts and opinion.
Why would a CEO initiate a halt on Friday, with a goal date the next day? We can assume he received a decision from FDA. If that's the case, why the halt? Many believe it is because he didn't want news to leak out. This doesn't add up, because this is a small group of people, and not a huge corporation, with hundreds of executives to be concerned with about spilling the beans. In fact, it is likely that he himself, was the only one privy to the information. It's possible this was done to avoid perception of insider trading, but as stated earlier, the insider class is small.
If the news was bad, (delay or denial) why halt the stock? He could have allowed the stock to trade out, and released the news after the market close, which he didn't. On the other hand, if the news is good, what better way to send a message or flare to the market and investors to stay tuned. In other words, why halt the stock, drawing attention to it, and then release disappointing news? That would make no sense.
Some might argue the CEO can't initiate a halt like that, but on the TSX he can, and the OTC has to follow suit. The authorities and exchange wouldn't be privy to a news event, and they don't halt automatically because of an upcoming goal date.
In the past CRL's and delays didn't cause a halt. In my opinion, they have their approval, and the CEO is taking his time writing and preparing his PR, and how and where it will be released.
I don't usually like to post information, that might cause someone to buy and lose money. However, this is safe situation, because we will all find out together.
Hey, it's only my thoughts and opinion.
Recent PHRRF News
- PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness • Newsfile • 04/21/2026 12:00:00 PM
- PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides • Newsfile • 04/20/2026 12:00:00 PM
- PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery • Newsfile • 04/16/2026 12:00:00 PM
- PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology • Newsfile • 04/13/2026 12:00:00 PM
- PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches • Newsfile • 03/26/2026 12:00:00 PM
- PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market • Newsfile • 03/03/2026 01:00:00 PM
- PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success • Newsfile • 02/02/2026 02:27:00 PM
- PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs • Newsfile • 01/14/2026 01:00:00 PM
- PharmaTher CEO Publishes Letter to Shareholders • Newsfile • 01/02/2026 01:00:00 PM
- PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise • Newsfile • 12/02/2025 02:53:00 PM
- PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program • Newsfile • 11/17/2025 01:00:00 PM
- PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale • Newsfile • 10/17/2025 12:26:00 PM
- PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease • Newsfile • 10/16/2025 12:00:00 PM
- PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings • Newsfile • 10/15/2025 12:00:00 PM
- PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease • Newsfile • 10/08/2025 12:00:00 PM
- PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy • GlobeNewswire Inc. • 10/02/2025 12:00:00 PM
- PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments • Newsfile • 10/01/2025 12:00:00 PM
- PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments • GlobeNewswire Inc. • 10/01/2025 12:00:00 PM
- Psychedelic Pharma Stock Surges on FDA Breakthrough • AllPennyStocks.com • 08/11/2025 07:30:00 PM
